Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
5 lessons
12mA goal-by-goal map of the peptides people ask about most, scored on human evidence and regulatory status. The only ones with strong evidence are approved drugs; most of the rest are animal data. No vendors, no dosing.
6mARA-290 (cibinetide) explained: the EPO-derived peptide studied for small fiber neuropathy, what Phase 2 trials found, side effects, and FDA status.
5mKPV is a three-amino-acid fragment of α-MSH studied for inflammation, mostly in the gut and mostly in mice. Here's what's known, what's claimed and what's missing.
7mNovo Nordisk submitted CagriSema in December 2025. The fixed-dose amylin and GLP-1 combination remains investigational while FDA reviews the application.
10mKLOW is a vendor name for a four-peptide blend: BPC-157, TB-500, GHK-Cu and KPV in one vial. Here's what each ingredient is, what the research actually covers, how KLOW differs from GLOW and Wolverine, and where it stands with FDA.
Also available at /blog for legacy links.